[<i>In vitro</i> activity of β-lactamase inhibitors avibanvctam and relebactam in combination with β-lactams against multidrug-resistant <i>Mycobacterium tuberculosis</i> and mutations of resistance genes].
Jie Shi, Dong-yuan Zheng, X G, Ruyue Su, Yating Zhu, S H Wang, Wei‐Jen Chang, Guixin Sun, et al. (9 authors)
PubMed · 2023-08
Abstract
Both avibactam and relebactam had better synergistic effects on β-lactams than clavulanic acid. The combination of tebipenem and relebactam showed the most potent activity against MDR-TB isolates. In addition, the Ser111Arg and Asn213Thr substitution of BlaC may be associated with an increased susceptibility of MDR-TB isolates to meropenem in the presence of clavulanate.
MeSH terms
- Clavulanic acid
- Meropenem
- Microbiology
- Mycobacterium tuberculosis
- Carbapenem
- Avibactam
- Biology
- Minimum inhibitory concentration
- Imipenem
- Ertapenem
- Tuberculosis
- Medicine
- Antimicrobial
- Amoxicillin
- Antibiotics